Previous 10 | Next 10 |
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 7.2% to $0.04 on volume of 426,309,096 shares PROSHARES TRUST (SQQQ) rose 1.8% to $12.07 on volume of 171,048,374 shares AGBA Group Holding Limited (AGBA) rose 157.5% to $1.03 on volume of 121,894,6...
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering mak...
2024-04-18 06:52:32 ET Summary Proposed bill may fast track TikTok's divestment from ByteDance or face a U.S. ban. Micron Technology to receive funding from the U.S. for chipmaking projects. 23andMe CEO eyes taking DNA-testing company private. Listen below or on the ...
2024-04-18 04:44:39 ET More on 23andMe 23andMe (ME) Q3 2024 Earnings Call Transcript 23andMe falls 20% after earnings, breakup speculation Seeking Alpha's Quant Rating on 23andMe Historical earnings data for 23andMe Read the full article on Seeking ...
2024-04-15 22:15:03 ET Citigroup analyst issues NEUTRAL recommendation for ME on April 15, 2024 08:50PM ET. The previous analyst recommendation was Neutral. ME was trading at $0.4016 at issue of the analyst recommendation. Historical Analyst Recommendations Latest ...
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, antibody targeting CD200R1: Preclinical data will be presented on targetin...
2024-03-24 03:23:00 ET If you're an individual investor who wants to invest like a billionaire fund manager, I've got good news. Following billionaires is relatively easy because the U.S. Securities and Exchange Commission makes anyone who manages over $100 million in assets report their tr...
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH S...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for 23andMe+ Premium and Total Health members, that uncovers DNA connections to 335 unique historical individu...
SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Hea...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at h...
2024-06-04 12:48:12 ET Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal ...